Long-term inhibition of glioma growth by systemic administration of human PEX

Journal of Neurosurgical Sciences

Volumn 47, Issue 2, 2003, Pages 69-78

  Pluderi, M ^a   Lucini, V ^a   Caronzolo, D ^a   Pannacci, M ^a   Costa, F ^a   Carrabba, G ^a   Giussani, C ^a   Grosso, S ^a   Colleoni, F ^a   Scaglione, F ^a   Villani, R ^a   Bikfalvi, A ^b   Bello, L ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b INSERM   (France)

Author keywords

Angiogenesis inhibitors; Endogenous inhibitors; Glioma, therapy

Indexed keywords

ANGIOGENESIS INHIBITOR; PROTEIN; PROTEIN PEX; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER INVASION; CANCER TRANSPLANTATION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; GLIOMA; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; NUDE MOUSE;

ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL DIVISION; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; GLIOMA; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PEPTIDE FRAGMENTS; POLYMERASE CHAIN REACTION; RECOMBINANT PROTEINS; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 10744228124     PISSN: 00264881     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-85.
2. Cao Y. Endogenous angiogenesis inhibitors and their therapeutic implications. Int J Biochem Cell Biol 2001;33:357-69.
3. Sipos EP, Brem H. Local anti-angiogenic brain tumor therapies. J Neurooncol 2000;50:181-8.
4. Brower V. Endostatin "cell factories" shrink rodent brain tumors. Trends Mol Med 2001;7:97-8.
5. Nguyen JT, Wu P, Clouse ME, Hlatky L, Terwillinger EF. Adeno-associated virus mediated delivery of anti angiogenic factors as an antitumor strategy. Cancer Res 1998;58:5673-7.
6. Klement G, Baruchel S, Rak J, et al. Continuous low-dose therapy with vinblastin and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Investig 2000;105:R15-24.
7. Tanaka T, Cao Y, Folkman J, Fine HA. Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth. Nat Med 1997;3:437-42.
8. Herbst RS, Lee AT, Tran HT. MD Anderson Center Trail of human endostatin. Curr Oncol Rep 2001;3:131-40.
9. O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and. sustains dormancy of human primary tumors in mice. Nat Med 1996;2:689-92.
10. Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997;27;390:404-7.
11. Mishima K, Johns TG, Luwor et al. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor. Cancer Res 2001;61:5349-54.
12. Kirsch M, Strasser J, Allende R, Bello L, Zhang J, Black PM. Angiostatin suppresses malignant glioma growth in vivo. Cancer Res 1998;58:4054-9
13. Im SA, Gomez-Manzano C, Fueyo J, Liu T, KE LD, Kim JJ et al. Antiangiogenesis treatment for gliomas: transfer of antisense-vascular endothelial growth factor inhibits tumor growth in vivo. Cancer Res 1999;59:895-900.
14. Joki T, Machluf M, Atala, A, Zhu J, Seyfried NT, Dunn IF et al. Continuous release of endostatin from microencapsulated engineered cells for tumory therapy. Nat Biotechnol 2001;19:35-9.
15. Kerbel RS, Yu J, Tran J, Man S, Viloria-Petit A, Klement G et al. Possibile mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches. Cancer Metastasis Rev 2001;20:79-86.
16. Yu JL, Rak JW, Coomber BL, Hicklin DJ, Kerbel RS. Effect of p53 status on tumor response to antiangiogenic therapy. Science 2002;295:1526-8.
17. Rak J, Yu JL, Kerbel RS, Coomber BL. What do oncogenic mutations have to do with angiogenesis/vascular dependance of tumors? Cancer Res 2002;62:1931-4.
18. Bello L, Lucini V, Carrabba G, Giussani C, Machluf M, Pluderi M et al. Simultaneous inhibition of glioma angiogenesis, cell proliferation and invasion by a naturally occurring fragment of human metalloproteinase-2. Cancer Res 2001;61:8370-6.
19. Bello L, Carrabba G, Giussani C, Lucini V, Cerutti F, Scaglione F et al. Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo. Cancer Res 2001;61:7501-6.
20. Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH. Different signal transduction properties of KDR and flt-1, 2 receptors for vascular endothelial growth factor. J BiolChem 1994;269:26988-95.
21. Deroanne CF, Hajitou A, Calberg CM, Nusgens BV, Lapiere CM. Angiogenesis by fibroblast growth factor-4 is mediated trough an autocrine up-regulation of vascular endothelial growth factor expression. Cancer Res 1997;57:5590-7.
22. Friedlander DR, Zagzag D, Sciff B, Cohen H, Allen JC, Kelly PJ et al. Migration of brain tumor cells on extracellular matrix proteins in vitro correlates with tumor type and grade and involves αv and β1 integrins. Cancer Res 1996;56:1939-47.
23. Rusnati M, Tanghetti E, Dell'Era P, Gualandris A, Presta M. αvβ3 integrin mediates the cell-adhesive capacity and biological activity of basic Fibroblast Growth Factor in cultured endothelial cells. Mol Biol Cell 1997;8:2449-61.
24. Weidner N, Semple J, Welch W, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8.
25. Leon SP, Folkerth R, Black PM. Microvessel density is a prognostic indicator for patients with astroglial brain tumors. Cancer 1996;77:362-72.
26. Bello L, Francolini M, Marthyn P, Zhang J, Carroll RS, Nikas DC et al. αvβ3 and αvβ5 integrin expression in glioma periphery. Neurosurgery 2001;49:380-9.